ALGRX 2872Alternative Names: ALGRX2872
Latest Information Update: 01 Nov 2005
At a glance
- Originator AlgoRx Pharmaceuticals
- Class Antimigraines
- Mechanism of Action Serotonin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 26 Oct 2005 Discontinued - Clinical-Phase-Unknown for Migraine in USA (unspecified route)
- 03 Mar 2003 Clinical trials in Migraine in USA (unspecified route)